The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 6 of the 20 sources its claims cite were checked for support.
Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey
Open accessAbstract
Background: Acute benzodiazepine withdrawal has been described, but literature regarding the benzodiazepine-induced neurological injury that may result in enduring symptoms and life consequences is scant. Objective: We conducted an internet survey of current and former benzodiazepine users and asked about their symptoms and adverse life events attributed to benzodiazepine use. Methods: This is a secondary analysis of the largest survey ever conducted with 1,207 benzodiazepine users from benzodiazepine support groups and health/wellness sites who completed the survey. Respondents included those still taking benzodiazepines (n = 136), tapering (n = 294), or fully discontinued (n = 763). Results: The survey asked about 23 specific symptoms and more than half of the respondents who experienced low energy, distractedness, memory loss, nervousness, anxiety, and other symptoms stated that these symptoms lasted a year or longer. These symptoms were often reported as de novo and distinct from the symptoms for which the benzodiazepines were originally prescribed. A subset of respondents stated that symptoms persisted even after benzodiazepines had been discontinued for a year or more. Adverse life consequences were reported by many respondents as well. Limitations: This was a self-selected internet survey with no control group. No independent psychiatric diagnoses could be made in participants. Conclusions: Many prolonged symptoms subsequent to benzodiazepine use and discontinuation (benzodiazepine-induced neurological dysfunction) have been shown in a large survey of benzodiazepine users. Benzodiazepine-induced neurological dysfunction (BIND) has been proposed as a term to describe symptoms and associated adverse life consequences that may emerge during benzodiazepine use, tapering, and continue after benzodiazepine discontinuation. Not all people who take benzodiazepines will develop BIND and risk factors for BIND remain to be elucidated. Further pathogenic and clinical study of BIND is needed.
Overview
CoChat Summary
TL;DR
This secondary analysis of the largest internet survey of benzodiazepine users reports that many respondents experienced prolonged symptoms, often lasting a year or longer, and adverse life consequences attributed to benzodiazepine use, tapering, or discontinuation. The authors propose the term benzodiazepine-induced neurological dysfunction (BIND) for this constellation of enduring symptoms and life consequences.
Key findings
- Among 1,207 respondents, 88.1% reported anxiety, nervousness, or fear; 86.9% sleep disturbances; 86.2% low energy; and 85.3% difficulty focusing or distractedness. Overall, 76.6% of affirmative symptom answers reported durations of months or “one year or longer.”
- Of those reporting specific symptoms, over half said the symptom lasted ≥1 year: low energy 59.9%, difficulty focusing/distractedness 58.3%, memory loss 57.5%, nervous/anxiety 57.0%, sleep disturbances 56.4%, sensitivity to sights and sounds 54.3%, digestive issues 52.2%, symptoms triggered by food or drink 52.0%, muscle weakness 51.2%, and body aches/pains 50.7%.
- Many symptoms were reported as not matching the original prescription reason: restlessness 95.3%, muscle spasms 88.8%, pain/nerve spasms 88.1%, digestive/stomach/gut issues 75.8%, insomnia 57.5%, and situational anxiety/anxiety 55.6%.
- Over 90% attributed one or more general adverse life consequences to benzodiazepine use; respondents averaged 8.1 of 16 adverse life consequences. Specific consequences included significantly affected marriage/other relationships 56.8%, suicidal thoughts or attempted suicide 54.4%, lost a job/fired/unable to work 46.8%, and lost savings or retirement funds 26.7%. Among 426 respondents off benzodiazepines for ≥1 year, 55.9% to 83.6% rated life consequences as severe or worse.
Methods
- Secondary analysis of an internet survey of 1,207 current and former benzodiazepine users recruited through benzodiazepine support groups and health/wellness sites; respondents were taking full-dose benzodiazepines (n=136), tapering (n=294), or fully discontinued (n=763).
- The survey asked about 23 symptoms, their duration, original prescription reasons, and adverse life consequences; questions and multiple-choice answers were derived from a subset of benzodiazepine-associated symptoms reported by Ashton and Wright.
- Initial results were produced with SAS; subsequent analysis used a custom SQL Server data model and customized queries to examine correlations among prescription reasons, protracted symptoms, and adverse life consequences.
Limitations
- Stated: self-selected internet survey with no control group; no independent psychiatric diagnoses could be made; recruitment primarily through benzodiazepine support group websites may not represent all benzodiazepine users; anonymous survey with no access to medical records to confirm benzodiazepine use or status; multiple-choice format; symptoms were a subset and may not reflect the complete range; no exclusion criteria for old age, comorbidities, or substance use disorder; respondents were not asked about other sedating or non-benzodiazepine hypnotic drugs; no baseline symptom comparison across the benzodiazepine use trajectory.
- Evident: cross-sectional, self-reported attribution cannot establish causality between benzodiazepine use and symptoms or life consequences; support-group recruitment likely selects for more severe or distressing experiences; the paper notes statistical correlations between specific life consequences and symptoms could not be drawn.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 6 Not checked · 44 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Since benzodiazepines are among the most frequently prescribed drugs in the United States, treatments for BIND represent an urgent unmet medical need [25].”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Discussion
What the sources say
- Supportedcites [25] DT Maust, 2019, Benzodiazepine Use and Misuse Among Adults in the United States, Psychiatr Serv source
The Introduction (page unavailable) says benzodiazepines are prescribed to over 5% of U.S. adults and that use is growing. The Results (page unavailable) report 25.3 million adults using them as prescribed in the past year. These passages support the citing sentence’s broad characterization of benzodiazepines as frequently prescribed in the United States. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Patients in our survey sometimes wrote in comments that they felt like healthcare professionals did not take them seriously or frankly challenged or disbelieved their long-lasting symptoms [9].”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Discussion
What the sources say
- Supportedcites [9] A Finlayson, 2022, Experiences with benzodiazepine use, tapering, and discontinuation: an Internet survey, Ther Adv Psychopharmacol source
The Discussion/conclusion (page unavailable) says some respondents wrote comments criticizing healthcare professionals who minimized their distress or disbelieved their symptoms. It also reports that withdrawal symptoms could last months or years. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“On average, each respondent had 8.1 of the 16 adverse life consequences.”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, the prolonged symptoms after benzodiazepine use, tapering, or cessation frequently did not match the reason for which the benzodiazepines were originally prescribed.”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This study shows that over 80% of respondents identified more than five serious life consequences which they attributed to benzodiazepine use.”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
20 more claims
Create a free account to see all 57 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with other published studies and clinical observations, this scoping review showed that some people can discontinue benzodiazepines even after prolonged exposure with relatively little problem [12,13,23].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many respondents stated they had multiple symptoms, with over 40% reporting more than 17 symptoms lasting for over a year.”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the largest survey to date of individuals who reported taking benzodiazepines long term, approximately two-thirds of 1,200 active and former benzodiazepine users reported de novo symptoms that commenced early in the course of benzodiazepine therapy or upon its cessation [13].”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“More than half of respondents’ reported symptoms began early in the treatment and lasted for more than one year after discontinuation.”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Among the most frequently reported symptoms were: low energy, difficulty focusing, memory loss, nervousness or anxiety, and sleep disturbances.”
From Long-term neurological consequences following benzodiazepine exposure: A scoping review (2025) · cites this paper as [13]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Discussion
“This analysis showed ≥ 17 symptoms of ≥ 1 year’s duration post-discontinuation were reported by over 40% of respondents.”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Results
“More than half of all respondents (54.7%) experienced 17 or more symptoms of the 23 listed; and over 40% of these stated the symptoms as lasting “one year or longer.””
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Lost a job, fired, became unable to work | 585 (46.8%) | 18.5”
§ Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey > Results
Reported 46.8 · recomputed 48.467274
Citations
Cites
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Cognitive Effects of Long-Term Benzodiazepine Use: A Meta-Analysis
Barker, M. J., Greenwood, K. M., Jackson, M., & Crowe, S. F. (2004) · CNS Drugs · doi:10.2165/00023210-200418010-00004 · Cited by 552
The diagnosis and management of benzodiazepine dependence
Ashton, H. (2005) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000165594.60434.84 · Cited by 455 · cited 4×
“The questions and multiple-choice answers used in the survey were derived from a subset of a longer list of benzodiazepine-associated symptoms report by Ashton [12] and Wright [1].”
BackgroundMethodInfluentialBenzodiazepine Use and Misuse Among Adults in the United States
Maust, D. T., Lin, L. A., & Blow, F. C. (2019) · Psychiatric Services · doi:10.1176/appi.ps.201800321 · Cited by 337 · cited 1×
“among the most frequently prescribed drugs in the United States, treatments for BIND represent an urgent unmet medical need [25].”
BackgroundAcute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265 · cited 1×
“These findings and the results of our earlier reports [9, 10] conflict with some of the literature [11].”
ResultManagement of benzodiazepine misuse and dependence
Brett, J., & Murnion, B. (2015) · Australian Prescriber · doi:10.18773/austprescr.2015.055 · Cited by 260 · cited 1×
“Since benzodiazepine users are a heterogeneous population, it is unlikely there is a one-size-fits-all approach to tapering and discontinuation [24].”
BackgroundThe Residual Medium and Long-term Cognitive Effects of Benzodiazepine Use: An Updated Meta-analysis
Crowe, S. F., & Stranks, E. K. (2018) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acx120 · Cited by 209 · cited 1×
“A meta-analysis of cognitive effects found that long-term benzodiazepine users were more impaired in all cognitive categories than the controls [19, 20].”
BackgroundBenzodiazepines Remain Important Therapeutic Options in Psychiatric Practice
Dubovsky, S. L., & Marshall, D. (2022) · Psychotherapy and Psychosomatics · doi:10.1159/000524400 · Cited by 171
Protracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 1×
“Although protracted symptoms following discontinuation of benzodiazepine use have been reported previously [9, 13, 14], it has generally been tacitly assumed that these symptoms were withdrawal phenomena that would resolve with time.”
BackgroundBenzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Research works printed but not linked: 1
- Food and Drug Administration. Integrated drug utilization, epidemiology, and pharmacovigilance review: Benzodiazepine use, misuse, abuse, dependence, withdrawal, morbidity, and mortality Rockville, Maryland: Food and Drug Administration; 2020 [Available from: https://www.benzoinfo.com/wp-content/uploads/2020/11/Benzodiazepine-Information-Coalition-FOIA-FDA-.pdf/.
Cited by
Brandt, J., Bressi, J., Lê, M.-L., Neal, D., Cadogan, C., Witt-Doerring, J., Witt-Doerring, M., & Wright, S. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2024.102507 · Cited by 77
“15,16 19 The perspective that various guidelines on BZD prescribing have been largely concordant with one another for common mental health and sleep concerns, while commonly held among clinicians and academics, has not yet been subject to rigorous scrutiny to examine differences between…”
BackgroundBrunner, E., Chen, C.-Y. A., Klein, T., Maust, D., Mazer-Amirshahi, M., Mecca, M., Najera, D., Ogbonna, C., Rajneesh, K. F., Roll, E., et al. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09499-2 · Cited by 51
“133”
Simone, M. D., Feo, R. D., Choucha, A., Ciaglia, E., & Fezeu, F. (2023) · Medical Sciences · doi:10.3390/medsci12010002 · Cited by 20
“In the long term, benzodiazepines can lead to dependence, with a withdrawal syndrome in about one-third of subjects after no more than 4 to 6 weeks of regular administration [29].”
BackgroundLynch, T., Ryan, C., Huff, C., Foster, D. E., & Cadogan, C. (2024) · Health Expectations · doi:10.1111/hex.13962 · Cited by 11
“31 It is postulated that these symptoms may begin while taking or tapering BZRAs, and can persist following discontinuation for weeks, months or even years.”
BackgroundSelf-citationHelping people to discontinue antipsychotics: if, when and how
Moncrieff, J., & Horowitz, M. A. (2025) · Schizophrenia · doi:10.1038/s41537-025-00695-x · Cited by 11
“This is also likely to be explained by the underlying nature of the condition to some extent, but it may also re fl ect the consequences of antipsychotic withdrawal, analogous to the protracted withdrawal states that have been reported following benzodiazepine and antidepressant withdrawal 84 – 87 .”
Metadata
- Authors
- Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R.
- Affiliations
- University of Colorado Anschutz (US)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Ritvo, Alexis D.
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2023-06-29
- Volume
- 18
- Issue
- 6
- Pages
- e0285584
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC10309976
- OpenAlex
- W4382599949
- Semantic Scholar
- cd92b2a9bc669127d49d8def3d855d6cc2af3839
- Cited by
- 38
- References
- 29
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 10 · 2023: 2
- FWCI
- 7.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Brigham and Women's Hospital
- Kaiser Permanente
- Tulane University
- University of South Carolina
- Trinity College Dublin
- Griffith University
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- benzodiazepine withdrawal, benzodiazepine tapering, benzodiazepine discontinuation, memory loss, anxiety, low energy
- MeSH terms
- Amnesia, Anxiety, Anxiety Disorders, Benzodiazepines, Humans, Control Groups
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. https://app.cochat.ai/papers/10.1371/journal.pone.0285584
- The paper
- Ritvo, A. D., Foster, D. E., Huff, C., Finlayson, A. J. R., Silvernail, B., & Martin, P. R. (2023). Long-term consequences of benzodiazepine-induced neurological dysfunction: A survey. PLOS ONE. https://doi.org/10.1371/journal.pone.0285584
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.